Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02044445
Other study ID # UHR-10
Secondary ID
Status Completed
Phase N/A
First received October 10, 2013
Last updated May 26, 2014
Start date November 2009

Study information

Verified date May 2014
Source Aristotle University Of Thessaloniki
Contact n/a
Is FDA regulated No
Health authority Greece: Ministry of Health and Welfare
Study type Interventional

Clinical Trial Summary

During controlled ovarian hyperstimulation (COH), human chorionic gonadotrophin (hCG) is administered to trigger the final follicular maturation before oocyte retrieval, in an attempt to mimic the physiologic effects of LH. The hCG is administered when more than three follicles ≥17mm in mean diameter have developed.

The time interval between hCG administration and oocyte retrieval is of critical importance since the time after luteinizing stimulus is a period of intense processes including the start of luteinization, expansion of cumulus cells and oocyte meiotic maturation.

The commonly practiced hCG administration time of 33 to 36 h in most IVF cycles aims to avoiding spontaneous ovulation before oocyte retrieval. However, several studies have shown that significantly more high quality embryos have been obtained with a prolonged hCG-to-oocyte interval of 38 h. It has been hypothesized that longer interval would be beneficial in improving oocyte quality and achieving optimal maturation.

Currently there are no data on the effect of the time interval between hCG administration and oocyte retrieval on IVF outcome in GnRH antagonist cycles. The aim of this study is to determine whether there is any difference in in vitro fertilization outcome when oocyte retrieval takes place at 36 h or 38 h following hCG administration


Recruitment information / eligibility

Status Completed
Enrollment 154
Est. completion date
Est. primary completion date December 2013
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 43 Years
Eligibility Inclusion Criteria:

- women undergoing fresh IVF cycle with recombinant FSH and GnRH antagonists

- regular spontaneous menstrual cycle (24-35 days)

- age = 43 years

- FSH = 20 IU/L

Exclusion Criteria:

- History of previous ovarian surgery

- Women with Stage III-IV Endometriosis

- Women undergoing natural cycle IVF

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Oocyte retrieval will be performed 36 h or 38 h after hCG administration
Oocyte retrieval will be performed 36 h or 38 h after hCG administration

Locations

Country Name City State
Greece Unit for Human Reproduction, 1st Dept of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki Thessaloniki

Sponsors (1)

Lead Sponsor Collaborator
Aristotle University Of Thessaloniki

Country where clinical trial is conducted

Greece, 

Outcome

Type Measure Description Time frame Safety issue
Primary retrieval rate (cumulus-oocyte complexes/ follicles> 11 mm) up to 38 h after hCG administration No
Secondary Clinical pregnancy rate (evidence of intrauterine sac with fetal heart activity at 6-8 weeks of gestation) At 6-8 weeks of gestation No
Secondary Total number of oocytes retrieved up to 38 h after hCG administration No
See also
  Status Clinical Trial Phase
Completed NCT03569787 - Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire
Completed NCT03105453 - The Microbiome in Subfertility and Assisted Reproductive Technologies (ART)
Terminated NCT02180256 - Effect of Endometrial Scratching on Assisted Reproduction Outcomes: a Randomized Controlled Trial N/A
Terminated NCT02197832 - A RCT on the Effect of Endometrial Injury on Improving Ongoing Pregnancy Rate in Subfertile Women Undergoing FET Cycles N/A
Completed NCT00971152 - Effect of a Higher Than Maximum 450IU Gonadotropin Dose in an In-vitro Fertilization Cycle Phase 3
Completed NCT01569945 - Hormonal Stimulation in IUI Treatment: Is Clomifen Combined With Ethinyl Estradiol Better, Worse or Equal to Menopur N/A
Recruiting NCT04064840 - GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET Phase 3
Recruiting NCT02561793 - DHEA Versus Placebo in Women With Poor Ovarian Response Phase 3
Terminated NCT02570386 - Clinical Effectiveness of Frozen Thawed Embryo Transfer Compared to Fresh Embryo Transfer N/A
Completed NCT02197208 - A RCT Comparing Spontaneous Natural Cycles and Human Chorionic Gonadotrophin-induced Natural Cycles in FET N/A
Completed NCT01961336 - Transdermal Testosterone Pretreatment in Poor Responders Undergoing IVF Phase 3
Completed NCT02487940 - Assessment of Intralipid Efficacy in Women With Unexplained Recurrent Implantation Failure Phase 4
Completed NCT01385618 - Gene-polymorphisms Relating to Human Subfertility N/A
Completed NCT00985062 - Mild Versus Conventional Ovarian Stimulation Treatment for In Vitro Fertilization N/A
Recruiting NCT04538560 - Preimplantation Genetic Testing for Aneuploidy of Polar Bodies N/A
Completed NCT02748278 - Comparison of the Number of Oocytes Obtained Between Chinese and Caucasian Women in IVF Treatment
Completed NCT02863614 - Analgesia for Endometrial Scratching N/A
Completed NCT02151006 - Does Dehydro Epiandrosterone (DHEA) Improve Pregnancy Rate in Women Undergoing IVF/ICSI With Expected Poor Ovarian Response? Phase 3
Completed NCT02154958 - Role of Follicular Output Rate in the Prediction of in Vitro Fertilization and Intracytoplasmic Sperm Injection in Women With Unexplained Infertility N/A
Completed NCT01067664 - Prognostic Value of Progesterone for In Vitro Fertilization (IVF) Outcome N/A